Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 215

The DOI matches its Crossref record; 1 of the 1 references it cites were found in a registry or an index.

An Expression Signature Classifies Chemotherapy-Resistant Pediatric Osteosarcoma

Mintz, Michelle B., Sowers, Rebecca, Brown, Kevin M., Hilmer, Sara C., Mazza, BethAnne, Huvos, Andrew G., Meyers, Paul A., LaFleur, Bonnie, McDonough, Wendy S., Henry, Michael M., Ramsey, Keri E., Antonescu, Cristina R., Chen, Wen, Healey, John H., Daluski, Aaron, Berens, Michael E., MacDonald, Tobey J., Gorlick, Richard, Stephan, Dietrich A.·2005·Cancer Research

Abstract

Osteosarcoma is the most common malignant bone tumor in children. Osteosarcoma patients who respond poorly to chemotherapy are at a higher risk of relapse and adverse outcome. Therefore, it was the aim of this study to identify prognostic factors at the time of diagnosis to characterize the genes predictive of poor survival outcome and to identify potential novel therapeutic targets. Expression profiling of 30 osteosarcoma diagnostic biopsy samples, 15 with inferior necrosis following induction chemotherapy (Huvos I/II) and 15 with superior necrosis following induction chemotherapy (Huvos III/IV), was conducted using Affymetrix U95Av2 oligonucleotide microarrays. One hundred and four genes were found to be statistically significant and highly differentially expressed between Huvos I/II and III/IV patients. Statistically significant genes were validated on a small independent cohort comprised of osteosarcoma xenograft tumor samples. Markers of Huvos I/II response predominantly were gene products involved in extracellular matrix (ECM) microenvironment remodeling and osteoclast differentiation. A striking finding was the significant decrease in osteoprotegerin, an osteoclastogenesis inhibitory factor. Additional genes involved in osteoclastogenesis and bone resorption, which were statistically different, include annexin 2, SMAD, PLA2G2A, and TGFβ1. ECM remodeling genes include desmoplakin, SPARCL1, biglycan, and PECAM. Gene expression of select genes involved in tumor progression, ECM remodeling, and osteoclastogenesis were validated via quantitative reverse transcription-PCR in an independent cohort. We propose that osteosarcoma tumor–driven changes in the bone microenvironment contribute to the chemotherapy-resistant phenotype and offer testable hypotheses to potentially enhance therapeutic response.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1158/0008-5472.can-04-2463

Cites

1 of 1 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 1 references

Cited by

See all 215

Metadata

Authors
Mintz, M. B., Sowers, R., Brown, K. M., Hilmer, S. C., Mazza, B., Huvos, A. G., Meyers, P. A., LaFleur, B., McDonough, W. S., Henry, M. M., Ramsey, K. E., Antonescu, C. R., Chen, W., Healey, J. H., Daluski, A., Berens, M. E., MacDonald, T. J., Gorlick, R., & Stephan, D. A.
Venue
Cancer Research
Published
2005-03-01
Volume
65
Issue
5
Pages
1748-1754
ISSN
  • 0008-5472 (ISSN-L)
  • 1538-7445
OpenAlex
W2138122497
Cited by
215
References
1
FWCI
12.08
Type
journal article
Language
en
Open access
closed

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: An Expression Signature Classifies Chemotherapy-Resistant Pediatric Osteosarcoma. https://app.cochat.ai/papers/10.1158/0008-5472.can-04-2463
The paper
Mintz, M. B., Sowers, R., Brown, K. M., Hilmer, S. C., Mazza, B., Huvos, A. G., Meyers, P. A., LaFleur, B., McDonough, W. S., Henry, M. M., Ramsey, K. E., Antonescu, C. R., Chen, W., Healey, J. H., Daluski, A., Berens, M. E., MacDonald, T. J., Gorlick, R., & Stephan, D. A. (2005). An Expression Signature Classifies Chemotherapy-Resistant Pediatric Osteosarcoma. Cancer Research. https://doi.org/10.1158/0008-5472.can-04-2463

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.